<DOC>
	<DOCNO>NCT01613170</DOCNO>
	<brief_summary>The use vaginal estrogen cream conjunction Toviaz effective use Toviaz alone treatment overactive bladder .</brief_summary>
	<brief_title>Premarin Versus Toviaz Treatment Overactive Bladder</brief_title>
	<detailed_description>Participants randomize two treatment arm 45 patient enrol study arm : Toviaz Premarin Vaginal Cream Toviaz Placebo Premarin Vaginal Cream . The Toviaz dose 4mg tablet give daily dose . Premarin vaginal cream dose 1 gram per vagina twice weekly . Compliance assess 4-week mark completion study , 8 week commencement treatment . The questionnaire choose study design validated effective tool assess evaluate OAB . Patients ask complete three symptom questionnaires 3-day void dairy . The questionnaire include Overactive Bladder Questionnaire ( OAB-q ) , The Patient Perception Bladder Condition , Urgency Severity Impact Questionnaire . The void diary questionnaire fill collected initial visit end study define 8 week commencement treatment . Additionally , patient ask rate symptom associate urogenital atrophy start study 8 week . The severity symptom grade base four-point scale ( 0=none , 1=mild , 2= moderate , 3=severe ) composite score generate . Examiners also rate severity sign urogenital atrophy first visit conclusion study . An objective evaluation effectiveness estrogen cream treatment accomplish pathological evaluation vaginal cell sample begin treatment 8 week point . These cell collect analyzed independent pathologist determine percentage parabasal , intermediate , superficial cell document change three category cell result vaginal estrogen treatment . A 3-Day voiding diary use document change baseline urinary urgency , frequency , incontinence episode . Based previous study predict 45 % improvement urinary frequency baseline use Toviaz vaginal Premarin cream . Secondary outcome measure use follow validated questionnaire give start study completion : OAB-q , Patient Perception Bladder Condition , Urgency Severity Impact Questionnaire .</detailed_description>
	<mesh_term>Urinary Bladder , Overactive</mesh_term>
	<mesh_term>Estrogens</mesh_term>
	<mesh_term>Estrogens , Conjugated ( USP )</mesh_term>
	<mesh_term>Fesoterodine</mesh_term>
	<criteria>Postmenopausal Women define least 12 month since last menstrual period OAB symptoms 6 month long complaint frequency ( 8 void 24 hour period ) , either 6 urgency episode 24 hour , either 3 urge urinary incontinence episode per 24 hour . Current recent treatment ( within last 6 month ) estrogens Past present history estrogen dependent neoplasm Undiagnosed genital tract bleed Current urinary vaginal infection History thromboembolic disorder associate estrogen use Commencement alteration diuretic therapy within three month study enrollment No contraindication anticholinergic medical therapy No contraindication estrogen therapy Symptoms must commence three year prior menopause Post Void Residual must equal 150 ml Recurrent Urinary Tract Infections ( 3 culture prove UTI 's within past 12 month ) Not anticholinergic medication last 4 week Painful Bladder Syndrome Chronic Pelvic Pain Vaginal Prolapse POPQ &gt; stage 2/ maximal prolapse point great +1 cm</criteria>
	<gender>Female</gender>
	<minimum_age>30 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2012</verification_date>
	<keyword>Overactive Bladder</keyword>
	<keyword>Vaginal Estrogen</keyword>
	<keyword>Anticholinergics</keyword>
	<keyword>Antimuscarinics</keyword>
</DOC>